- CureToday.com
- OncLive.com
- TargetedOnc.com
- CancerNetwork.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Satya Das, MD, MSCI | Authors
Articles
Satya Das, MD, MSCI, on the Impact of PRRT in Patients With Well-Differentiated NETs
January 27, 2021
The expert in hematology/oncology discussed the implications of a study which evaluated the use of peptide receptor radionuclide therapy in patients with well-differentiated neuroendocrine tumors.
Satya Das, MD, MSCI, on the Use of PRRT in Patients With Well-Differentiated NETs
January 25, 2021
The expert in hematology/oncology discussed the results of a study which evaluated the use of peptide receptor radionuclide therapy in patients with well-differentiated neuroendocrine tumors.
Satya Das, MD, MSCI, on the Design of a Study of PRRT in Patients With Well-Differentiated NETs
January 15, 2021
The expert in hematology/oncology spoke about the study which evaluated the use of peptide receptor radionuclide therapy in patients with well-differentiated neuroendocrine tumors.